Home
Opthea Limited
ASX Code
OPT
Sector
Pharmaceuticals- Biotechnology & Life Sciences
Investor Centre
https://opthea.com/annual-reports/
Website
https://opthea.com/
About
Opthea is committed to improving vision in patients suffering with retinal eye diseases. We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in combination with existing standard of care anti-VEGF-A therapies. OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.